Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers. 1992

V Hutt, and R Theodor, and G Pabst, and R Bonn, and E Fritschi, and H Jaeger
L.A.B. Gesellschaft für Pharmakologische Untersuchungen mbH & Co, Neu-Ulm, Federal Republic of Germany.

The objective of this study was to determine both the pharmacokinetic parameters and the bioavailability of two commercial 20-mg isosorbide-5-mononitrate (IS-5-MN) preparations (test and reference preparation) after single oral administration. For this purpose, the test and the reference preparation were examined in 24 healthy male volunteers according to a randomized 2-way cross-over design, blood samples were withdrawn up to 24 hours postadministration, and plasma concentrations of IS-5-MN were quantified by a gas chromatography (GC) method. Both preparations led to peak plasma levels of approximately 360 ng/mL IS-5-MN in the mean 0.76 hour (test) and 0.94 hour (reference preparation) after application; the plasma half-lives were about 5.2 hours, and for the areas under the curve (AUC(0-infinity)), mean values of 2741 (test preparation) and 2742 hour.ng/mL (reference preparation) were found. The statistical comparison (analysis of variance, confidence intervals) of the pharmacokinetic parameters found in the study resulted in bioequivalence of both IS-5-MN preparations. The undesired side effects/concomitant symptoms observed are known to occur after IS-5-MN administration.

UI MeSH Term Description Entries
D007548 Isosorbide Dinitrate A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action. Cardonit 40,Dilatrate,Iso-Bid,Isodinit,Isoket,Isoket Retard-120,Isomak R,Isordil,Isotrate,Nitrosorbide,Sorbitrate,Sorbonit,Dinitrate, Isosorbide,Iso Bid,IsoBid,Isoket Retard 120,Isoket Retard120
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013810 Therapeutic Equivalency The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease. Bioequivalence,Clinical Equivalency,Equivalency, Therapeutic,Generic Equivalency,Clinical Equivalencies,Equivalencies, Clinical,Equivalencies, Therapeutic,Equivalency, Clinical,Therapeutic Equivalencies,Bioequivalences,Equivalencies, Generic,Equivalency, Generic,Generic Equivalencies
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator

Related Publications

V Hutt, and R Theodor, and G Pabst, and R Bonn, and E Fritschi, and H Jaeger
February 1995, Arzneimittel-Forschung,
V Hutt, and R Theodor, and G Pabst, and R Bonn, and E Fritschi, and H Jaeger
December 1985, International journal of clinical pharmacology, therapy, and toxicology,
V Hutt, and R Theodor, and G Pabst, and R Bonn, and E Fritschi, and H Jaeger
January 1987, Cardiology,
V Hutt, and R Theodor, and G Pabst, and R Bonn, and E Fritschi, and H Jaeger
January 2002, Arzneimittel-Forschung,
V Hutt, and R Theodor, and G Pabst, and R Bonn, and E Fritschi, and H Jaeger
January 1982, Arzneimittel-Forschung,
V Hutt, and R Theodor, and G Pabst, and R Bonn, and E Fritschi, and H Jaeger
August 1999, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
V Hutt, and R Theodor, and G Pabst, and R Bonn, and E Fritschi, and H Jaeger
September 1989, International journal of clinical pharmacology, therapy, and toxicology,
V Hutt, and R Theodor, and G Pabst, and R Bonn, and E Fritschi, and H Jaeger
April 1981, Die Medizinische Welt,
V Hutt, and R Theodor, and G Pabst, and R Bonn, and E Fritschi, and H Jaeger
November 1987, Cardiologia (Rome, Italy),
V Hutt, and R Theodor, and G Pabst, and R Bonn, and E Fritschi, and H Jaeger
January 1981, Biopharmaceutics & drug disposition,
Copied contents to your clipboard!